Common Contracts
2 similar License Agreement contracts by Aveo Pharmaceuticals Inc
EX-10.1 2 aveo-ex101_191.htm EX-10.1 LICENSE AGREEMENTLicense Agreement • May 5th, 2020 • New York
This LICENSE AGREEMENT (this “Agreement”) is entered into as of August, 04, 2015 (the “Signing Date”) by and between JSC “Pharmstandard- Ufimskiy Vitamin Plant”, a company registered under the laws of the Russian Federation, with offices at Khudajberdina str., 28, Ufa, Bashkortostan, Russian Federation (hereinafter referred to as “Pharmstandard”) and AVEO PHARMACEUTICALS, INC., a Delaware corporation with its principal offices at One Broadway, 14th Floor, Cambridge, Massachusetts 02142, U.S.A. (“AVEO”). AVEO and Pharmstandard may each be referred to herein individually as a “Party” or, collectively, as the “Parties.”
LICENSE AGREEMENTLicense Agreement • November 9th, 2015 • Aveo Pharmaceuticals Inc • Pharmaceutical preparations • New York
Under the terms of the agreement, Pharmstandard is obligated to pay AVEO an upfront payment of $1.5 million. AVEO is also eligible to receive up to $7.5 million in connection with the first marketing authorization of tivozanib in Russia, $3.0 million for each additional approved indication thereafter and a high single-digit royalty on net sales in the above mentioned territories. Pharmstandard will be responsible for all activities and costs associated with the further development, regulatory filings, health services and commercialization of tivozanib in the specified territories. A percentage of all upfront, milestone and royalty payments received by AVEO are due to Kyowa Hakko Kirin as a sublicensing fee.
